darigabat + carbamazepine

Darigabat + carbamazepine is a combination of two antiepileptic drugs, each with distinct mechanisms of action. **Darigabat** (also known as CVL-865) is a selective positive allosteric modulator of GABA_A receptors, specifically targeting α2/3/5 subunits, under development for epilepsy and anxiety disorders. **Carbamazepine** is a classical anticonvulsant that acts primarily as a voltage-gated sodium channel inhibitor and is widely used in the management of epilepsy, bipolar disorder, and neuropathic pain. The combination may provide a broad spectrum of antiseizure activity, but care is required because carbamazepine is a known inducer of several cytochrome P450 enzymes, which can influence the pharmacokinetics of many drugs. No fixed-dose combination product of darigabat with carbamazepine is known to exist as of now; this entry refers to the concurrent use of these agents in clinical or investigational settings.